Caspase-3 Protein

Migration, Crosslink

📖

Caspase-3 Protein

active

wiki page Created: 2026-04-02T07:19:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-caspase-3-protein

📖 Wiki Page

protein2770 wordssynced 2026-04-02

Caspase-3 Protein

Overview

Pathway Diagram

```mermaid
flowchart TD
Caspase["Caspase Protease Enzyme"]

ROS_gene["ROS Oxidative Stress"]
AMPK_gene["AMPK Energy Sensor"]
HSP70_gene["HSP70 Heat Shock Protein"]
PPARG_gene["PPARG Metabolic Regulator"]

RIPK1_gene["RIPK1 Death Receptor Kinase"]
WNT_gene["WNT Signaling Pathway"]
STAT3_gene["STAT3 Transcription Factor"]

GSDME_protein["GSDME Gasdermin E"]
IL1B_protein["IL1B Interleukin-1beta"]

PANoptosis_process["PANoptosis Programmed Cell Death"]
Neurodegeneration_process["Neurodegeneration Neural Loss"]
ALS_disease["ALS Motor Neuron Disease"]

ROS_gene -->|"activates"| Caspase
AMPK_gene -->|"regulates"| Caspase
HSP70_gene -->|"protects"| Caspase
PPARG_gene -->|"modulates"| Caspase

RIPK1_gene -->|"activates"| Caspase
WNT_gene -->|"regulates"| Caspase
STAT3_gene -->|"interacts"| Caspase

Caspase -->|"cleaves"| GSDME_protein
Caspase -->|"activates"| IL1B_protein

Caspase -->|"triggers"| PANoptosis_process
Caspase -->|"drives"| Neurodegeneration_process
Neurodegeneration_process -->|"leads_to"| ALS_disease

GSDME_protein -->|"promotes"| PANoptosis_process
IL1B_protein -->|"enhances"| Neurodegeneration_process

style Caspase fill:#006494
style HSP70_gene fill:#1b5e20
style PPARG_gene fill:#1b5e20
style ROS_gene fill:#ef5350
style RIPK1_gene fill:#ef5350
style WNT_gene fill:#4a1a6b
style AMPK_gene f

...

Caspase-3 Protein

Overview

Pathway Diagram

Mermaid diagram (expand to render)

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Caspase-3 Protein</th>
</tr>
<tr>
<td class="label">Disease</td>
<td>Primary Trigger</td>
</tr>
<tr>
<td class="label">ALS</td>
<td>SOD1, TDP-43</td>
</tr>
<tr>
<td class="label">HD</td>
<td>Mutant huntingtin</td>
</tr>
<tr>
<td class="label">Stroke</td>
<td>Ischemia</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Caspase-3 Protein is a protein. This page describes its structure, normal nervous system function, role in neurodegenerative disease, and potential as a therapeutic target. [@yuan2010]

Caspase-3 (Cysteine-ASPartic protease-3), also known as CPP32, apopain, or SCA-1, is a member of the cysteine-aspartic protease (caspase) family that plays a central and critical role in programmed cell death (apoptosis). In the context of neurodegenerative diseases, caspase-3 activation represents a crucial executer of neuronal death pathways in Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), Huntington's disease (HD), and related disorders [1](https://pubmed.ncbi.nlm.nih.gov/12551937/). [@das2015]

Molecular Function and Biochemistry

Enzyme Classification and Structure

Caspase-3 belongs to the family of aspartate-specific cysteine proteases, classified as an effector caspase (along with caspase-6 and caspase-7), functioning downstream of initiator caspases (caspase-8, -9, -10) in the apoptosis cascade. The systematic name is EC 3.4.22.56, and the gene is located on chromosome 4q33 [1](https://pubmed.ncbi.nlm.nih.gov/12551937/). [@hyman2014]

The enzyme exists as an inactive zymogen (procaspase-3, 32 kDa) that requires proteolytic activation to generate the active heterotetramer. This activation involves cleavage at specific aspartic acid residues and subsequent dimerization of the p17/p12 subunits. [@damelio2012]

Domain Architecture

Caspase-3 contains distinct structural domains: [@friedlander2003]

N-terminal prodomain (~30 amino acids): Contains the caspase recruitment domain (CARD) that mediates interactions with upstream adaptor proteins like Apaf-1 and allows for activation by initiator caspases

Large subunit (p17, ~150 amino acids, 17 kDa): Contains the catalytic cysteine residue (Cys163) in the active site motif QACXG (where X is typically R or G), which is essential for proteolytic activity

Small subunit (p12, ~80 amino acids, 12 kDa): Forms the dimerization interface and contributes to substrate binding

The three-dimensional structure reveals a classic caspase fold with a central six-stranded β-sheet flanked by α-helices, with the active site formed at the interface between the two subunits. [@onyango2005]

Substrate Specificity and Recognition

Caspase-3 demonstrates high specificity for the tetrapeptide sequence DEXD (Asp-Glu-X-Asp), with optimal cleavage occurring after DXXD motifs. The S1 pocket shows absolute specificity for aspartate, while the S2-S4 pockets accommodate various amino acids, with preference for glutamic acid at S2 [1](https://pubmed.ncbi.nlm.nih.gov/12551937/). [@mattson2000]

Over 200 cellular substrates have been identified, classified into several functional groups: [@wolfe2013]

Structural and Cytoskeletal Proteins [@henderson2016]

Actin and tubulin: Essential for cytoskeletal integrity
Lamin A/C: Nuclear envelope maintenance
Vimentin: Intermediate filament structure
Spectrin: Membrane skeleton

DNA Repair and Maintenance Enzymes [@bredesen2016]

PARP (poly ADP-ribose polymerase): DNA repair
DNA-PKcs: Non-homologous end joining
Topoisomerase II: DNA topology

Signal Transduction Proteins

PKC isoforms: Signal transduction
STAT1: Transcription factor
AKT: Cell survival kinase

Anti-apoptotic Proteins

Bcl-2: Mitochondrial outer membrane permeabilization regulator
Mcl-1: Anti-apoptotic Bcl-2 family member
XIAP: Direct caspase inhibitor

Cell Cycle Regulators

p21cip1: Cyclin-dependent kinase inhibitor
Wee1: Cell cycle kinase

The cleavage of these substrates leads to the characteristic morphological and biochemical features of apoptosis, including chromatin condensation, DNA fragmentation, membrane blebbing, and formation of apoptotic bodies [2](https://pubmed.ncbi.nlm.nih.gov/14638856/).

Activation Mechanism

Caspase-3 activation occurs through a tightly regulated proteolytic cascade:

Initiator caspase activation: Caspase-8 (extrinsic pathway) or caspase-9 (intrinsic/mitochondrial pathway) become activated first through autoproteolysis or induced proximity

Procaspase-3 cleavage: Initiator caspases cleave procaspase-3 at specific aspartic acid residues (Asp175 in the interdomain linker and Asp9 at the N-terminus)

Autocatalytic processing: The cleaved procaspase-3 undergoes autocatalytic processing to generate the mature p17/p12 subunits

Dimerization: Two p17/p12 heterodimers form the active heterotetramer (32 kDa), which can then cleave substrates

Active site formation: The catalytic cysteine in the p17 subunit aligns with the substrate-binding pocket created at the dimer interface

This activation cascade ensures that caspase-3 activation occurs only after upstream death signals have been triggered, providing an important checkpoint in the cell death program.

Role in Neurodegenerative Diseases

Alzheimer's Disease

In Alzheimer's disease, caspase-3 contributes to multiple pathological processes, making it a central player in neuronal death [2](https://pubmed.ncbi.nlm.nih.gov/14638856/):

Amyloid-β-Induced Apoptosis
Amyloid-β42 oligomers trigger caspase-3 activation through multiple interconnected pathways:

Mitochondrial dysfunction: Aβ42 causes mitochondrial membrane potential loss, cytochrome c release, and subsequent activation of the intrinsic apoptosis pathway
Calcium dysregulation: Aβ42 elevates intracellular calcium levels, activating calcium-dependent proteases that contribute to caspase activation
Reactive oxygen species (ROS) generation: Oxidative stress from Aβ42 damages mitochondria and directly activates caspase-3
Neurotrophic factor signaling disruption: Aβ42 interferes with BDNF and other survival signals

Studies demonstrate that caspase-3 activation represents a final common pathway for Aβ42-induced neuronal death, and caspase-3 inhibitors protect against Aβ toxicity in cellular and animal models [2](https://pubmed.ncbi.nlm.nih.gov/14638856/).

Tau Cleavage and Pathology
Caspase-3 cleaves tau protein at Asp421, generating a truncation product with enhanced pathogenic properties [3](https://pubmed.ncbi.nlm.nih.gov/12591068/):

Aggregation promotion: The Δtau421 fragment has increased propensity for aggregation and filament formation
Propagation enhancement: Caspase-cleaved tau is more efficient at seeding tau pathology in recipient neurons
Microtubule disruption: Truncated tau more readily dissociates from microtubules
NFT formation: The fragment incorporates into neurofibrillary tangles

The caspase-cleaved tau fragment (Δtau421) is detected in AD brain tissue and is considered a pathogenic intermediate that drives disease progression [3](https://pubmed.ncbi.nlm.nih.gov/12591068/).

Synaptic Loss and Dysfunction
Caspase-3-mediated cleavage of synaptic proteins contributes to early synaptic dysfunction, a hallmark of AD:

Synaptic vesicle proteins: Synaptophysin, synaptotagmin cleavage disrupts neurotransmitter release
Postsynaptic density proteins: PSD-95, NMDA receptor subunit cleavage affects synaptic plasticity
Cytoskeletal proteins: Spine structure proteins are degraded

Correlation with Disease Progression
Caspase-3 activation correlates strongly with AD pathology:

Neurofibrillary tangle formation: Colocalization of active caspase-3 with NFTs
Neuronal loss: Particularly in vulnerable brain regions (hippocampus, entorhinal cortex, basal forebrain)
Clinical disease severity: Cognitive decline correlates with caspase-3 activity
Progression prediction: May predict progression from MCI to AD

Parkinson's Disease

In Parkinson's disease, caspase-3 plays multiple interconnected roles in dopaminergic neuron death [4](https://pubmed.ncbi.nlm.nih.gov/15962738/):

α-Synuclein Cleavage
Caspase-3 cleaves α-synuclein at multiple sites, generating pathogenic fragments:

Asp119 cleavage: Generates a fragment that enhances aggregation propensity
Asp123 cleavage: Produces a toxic truncation product that disrupts membrane integrity
Asp125 cleavage: Contributes to pathogenic aggregation and Lewy body formation

These cleaved fragments:

Seed aggregation of full-length α-synuclein
Form toxic oligomers that disrupt cellular homeostasis
Promote Lewy body formation
Facilitate prion-like propagation between neurons

Studies show that caspase-3 cleavage of α-synuclein is increased in PD brain tissue, and inhibition of cleavage reduces α-synuclein toxicity [4](https://pubmed.ncbi.nlm.nih.gov/15962738/).

Mitochondrial Dysfunction and Dopaminergic Neuron Vulnerability
Dopaminergic neurons are particularly vulnerable to caspase-3-mediated apoptosis due to their unique characteristics:

High metabolic demand: Substantia nigra neurons have high ATP requirements
Mitochondrial complex I deficiency: Characteristic of PD
Elevated ROS production: Dopamine metabolism generates reactive species
Calcium homeostasis disruption: Pacemaker activity leads to calcium flux

LRRK2 Interactions
Mutations in LRRK2 (the most common genetic cause of familial PD) significantly affect caspase-3 signaling:

G2019S mutation: Enhances caspase-3 activation through kinase-dependent mechanisms
R1441C/H/G mutants: Alter apoptotic thresholds in neurons
Kinase activity effects: LRRK2 kinase activity directly influences pro-apoptotic signaling

PINK1/Parkin Pathway Interactions
The PINK1/parkin mitophagy pathway intersects with caspase-3 in complex ways:

Parkin cleavage: Caspase-3 can cleave parkin, potentially disrupting its E3 ligase function
Mitophagy disruption: Caspase-3 activation affects mitochondrial quality control
Accumulation of damaged mitochondria: Leads to increased ROS and further damage

Amyotrophic Lateral Sclerosis (ALS)

In ALS, caspase-3 activation contributes to progressive motor neuron death [5](https://pubmed.ncbi.nlm.nih.gov/12421763/):

SOD1 Mutations
Mutant Cu/Zn superoxide dismutase (SOD1) proteins trigger caspase-3 activation through:

Direct interaction with mitochondria
Endoplasmic reticulum stress induction
Oxidative stress generation
Excitotoxicity amplification

TDP-43 Pathology
TAR DNA-binding protein 43 (TDP-43) aggregation, a hallmark of ALS:

Alters caspase-3 expression and activation
Contributes to transcriptional dysregulation
Promotes motor neuron vulnerability
Affects RNA processing of apoptosis-related genes

Mechanisms of Activation in ALS
Multiple interconnected mechanisms drive caspase-3 activation:

Oxidative stress: ROS from mutant SOD1 and mitochondrial dysfunction
Excitotoxicity: Glutamate-induced calcium influx
Mitochondrial dysfunction: Energy failure and cytochrome c release
Neuroinflammation: Activated microglia release pro-apoptotic factors

Huntington's Disease

Caspase-3 plays complex and sometimes paradoxical roles in Huntington's disease:

Mutant Huntingtin Cleavage
Mutant huntingtin (mHTT) protein is cleaved by caspase-3 at multiple sites:

Asp513 cleavage: Generates toxic fragments that accumulate in the cytoplasm
Asp552 cleavage: Contributes to pathogenesis through gain-of-toxic-function
Asp586 cleavage: Produces aggregation-prone fragments

These fragments:

Accumulate in the nucleus
Disrupt transcriptional regulation
Form nuclear inclusions
Cause widespread transcriptional dysregulation

Stroke and Ischemic Injury

Caspase-3 is a major mediator of neuronal death after stroke and cerebral ischemia:

Reperfusion Injury
Blood flow restoration paradoxically increases damage:

Calcium overload activates caspases
ROS burst triggers intrinsic pathway
Inflammation amplifies cell death

Excitotoxicity
Glutamate-induced excitotoxicity activates caspase-3:

NMDA receptor overactivation
Calcium influx
Mitochondrial dysfunction

Neuroprotective Strategies
Caspase-3 inhibition is neuroprotective in animal models:

Reduces infarct size
Improves functional outcomes
Extends treatment window

Therapeutic Targeting

Pharmacological Inhibitors

Several classes of caspase-3 inhibitors have been developed for neuroprotection [6](https://pubmed.ncbi.nlm.nih.gov/17656456/):

Peptide Inhibitors

DEVD-CHO: Cell-permeable tetrapeptide (Ac-DEVD-CHO)
Z-DEVD-FMK: Irreversible inhibitor, fluorescent version available
Ac-DEVD-CHO: Selective for caspase-3 over other caspases
VEID-CHO: Alternative sequence preference

Non-Peptide Inhibitors

Small molecule hydrazides
Pyrazolone derivatives
Quinoline-based inhibitors
Pyrroloindole derivatives

Natural Products with Caspase-3 Inhibitory Activity

Quercetin: Flavonoid with multiple cellular effects
Curcumin derivatives: Enhanced stability and potency
Epigallocatechin-3-gallate (EGCG): Polyphenol with neuroprotective properties
Resveratrol: SIRT1 activator with anti-apoptotic effects

Challenges in Drug Development

Despite promising preclinical data, significant challenges remain:

Blood-brain barrier penetration: Many inhibitors are too large or charged to enter the CNS

Temporal window: Intervention must occur early in the apoptotic cascade

Systemic effects: Caspase-3 is essential for normal cellular turnover and immune function

Apparent paradox: Benefits from caspase activation in some contexts (e.g., cancer therapy)

Alternative Strategies

Gene Therapy Approaches

Dominant-negative caspase-3 mutants
siRNA-mediated knockdown
CRISPR-based gene editing
Anti-sense oligonucleotides

Modulation of Upstream Pathways

Death receptor blockers
BCL-2 family modulators
Mitochondrial protectants
Antioxidants

Cell-Type Specific Targeting

Viral vector delivery to specific neurons
Antibody-drug conjugates
Exosome-mediated delivery
Focused ultrasound enhancement

Biomarker Potential

Caspase-3 activity serves as a potential biomarker for neurodegeneration [6](https://pubmed.ncbi.nlm.nih.gov/17656456/):

Cerebrospinal Fluid (CSF) Biomarkers

Elevated caspase-3 in AD, PD, and ALS patients
Correlates with disease severity
May predict progression from MCI to AD
Can be combined with other biomarkers

Blood-Based Biomarkers

Peripheral blood mononuclear cell (PBMC) caspase-3
Platelet caspase-3 activation
Plasma caspase-3 cleavage products

Imaging Biomarkers

Caspase-3-targeted PET ligands in development
Fluorescent probes for intraoperative imaging
Near-infrared dyes for in vivo imaging

Research Directions and Gaps

Recent Advances (2020-2024)

Caspase-3 in ferroptosis: Non-apoptotic role in iron-dependent cell death, distinct from classical apoptosis

Tau propagation: Caspase-cleaved tau fragments spread between neurons through synaptic connections

Microglial functions: Caspase-3 in neuroinflammation and microglial survival

Necroptosis crosstalk: Caspase-3 can cleave key necroptosis proteins (RIPK1, RIPK3)

Pyroptosis connections: Links between apoptosis and pyroptosis pathways

Epigenetic regulation: Non-coding RNAs (miRNAs, lncRNAs) regulating caspase-3

Single-cell analysis: Cell-type specific caspase-3 activation patterns

Critical Knowledge Gaps

Cell-type specific functions of caspase-3 in the brain
Temporal dynamics of activation in vivo
Biomarker validation in large clinical cohorts
Clinical trials of caspase inhibitors
Optimal timing and delivery methods
Distinguishing protective vs. harmful caspase-3 functions

Future Research Priorities

Development of brain-penetrant caspase-3 inhibitors
Identification of neuroprotective vs. pro-death caspase-3 functions
Biomarker development for patient stratification
Combination therapies targeting multiple pathways
Gene therapy approaches
Stem cell-based therapies with caspase modulation

Interactions and Signaling Networks

Protein-Protein Interactions

Caspase-3 interacts with numerous proteins in the apoptosis network:

Inhibitors

XIAP (X-linked inhibitor of apoptosis protein): Direct binding and inhibition
c-FLIP (cellular FLICE-like inhibitory protein): Blocks caspase-8 activation
Bcl-2 family anti-apoptotic proteins: Mitochondrial pathway regulation

Activators

Apaf-1 (apoptotic protease-activating factor 1): Forms apoptosome with cytochrome c
Cytochrome c: Released from damaged mitochondria
Smac/DIABLO: Neutralizes XIAP

Scaffolds and Adaptors

FADD: Death receptor signaling
TRADD: TNFR1 signaling
RAIDD: PIDDosome formation

Signaling Pathway Integration

Caspase-3 serves as a central hub integrating multiple cell death pathways:

Extrinsic pathway: Amplifies death receptor signaling through bid cleavage
Intrinsic pathway: Executes mitochondrial apoptosis
ER stress pathway: Mediates UPR-induced cell death
DNA damage pathway: Executes p53-dependent apoptosis
Mitophagy pathway: Links to mitochondrial quality control

Conclusion

Caspase-3 represents a central executor of neuronal death in neurodegenerative diseases. Its roles in AD, PD, ALS, HD, and stroke are multifaceted, involving substrate cleavage, protein aggregation, synaptic dysfunction, and neuroinflammation. While significant progress has been made in understanding its functions, significant challenges remain in translating this knowledge into effective therapies. The development of brain-penetrant, selective caspase-3 inhibitors and the identification of reliable biomarkers remain key research priorities for the neurodegenerative disease field.

External Links

[PubMed](https://pubmed.ncbi.nlm.nih.gov/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Biochemical Kinetics and Catalytic Mechanism

Catalytic Mechanism

Caspase-3 employs a classic cysteine protease catalytic mechanism:

[
The active site contains:- Oxyanion hole: Stabilize- S1 pocket: Absolute specificity for aspartate

S2-S4 pockets: Determine substrate sequence specificity

Kinetic Parameters

Kcat: ~1-10 s⁻¹
Km: ~1-50 μM (substrate-dependent)
Kcat/Km: ~10⁴-10⁵ M⁻¹s⁻¹

pH and Temperature Dependencies

Optimal pH: 7.0-7.5
Temperature optimum: 37°C
pH stability: 5.5-8.5

Regulation of Caspase-3 Activity

Transcriptional Regulation

Caspase-3 expression is regulated at multiple levels:

Promoter elements: p53, E2F, and other transcription factors
Alternative splicing: Multiple isoforms with different activities
mRNA stability: AU-rich elements in 3' UTR

Post-Translational Modifications

Phosphorylation

Ser residues: Phosphorylation can modulate activity
Kinases: PKA, CK2, and other kinases may phosphorylate caspase-3

Nitrosylation

S-nitrosylation of Cys163 inhibits activity
Occurs in NO-mediated neuroprotection

Glycosylation

N-linked glycosylation affects stability
May protect from proteasomal degradation

Cellular Localization

Caspase-3 distribution in neurons:

Cytoplasmic pool: Primarily localized in cytoplasm
Mitochondrial translocation: Released during apoptosis
Nuclear accumulation: In late apoptosis
Synaptic localization: Present at synapses

Neuronal Specificity

Why Neurons Are Particularly Vulnerable

Neuronal Apop

**Death rec--

Animal Models

Knock

**Cas- Embryonic- Neural tube closure defects

Surviving mice show enhanced resistance to some apoptotic stimuli

Conditional Knockout Models

Brain-specific deletion
Neuron-specific deletion
Inducible models

Transgenic Overexpression

Neuronal overexpression models
Fluorescent reporter models
Dominant-negative mutants

Species Differences

Rodents: Similar caspase-3 sequence and function
Primates: High conservation
Differences in regulation: Species-specific splicing

Clinical Implications

Diagnostic Applications

Therapeutic Implications

[@matsushita2005]

Comparative An### Common

Common execution via caspase-3
### Disease-S

Future Directions

Emerging Therapeutic Approaches

FRET-based sensors: Real-time activity monitoring
CRISPR screening: - Single-cell sequencing: Cell-type specifi

Summary

Caspase- Neuroinflammation modulation

Intercellul

Therapeutic targeting r- The balance between pro-death and homeostatic - The timing of intervention

Cell-type specific effects
Speci

Future rese- Developing brain-penetrant, selective inhibitors

Identifying bi- Understanding cell-type specific functions
Exploring combination therapies

References

[Thornberry et al., A combinatorial approach defines specificities of members of the caspase family and granzyme B (2002) (2002)](https://pubmed.ncbi.nlm.nih.gov/12551937/)

[Raina et al., Caspase-3: A protease implicated in Alzheimer's disease pathology (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/14638856/)

[Gamblin et al., Caspase cleavage of tau: Getting to the heart of the matter (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12591068/)

[Matsushita et al., Alpha-synuclein cleavage by caspase-3 (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15962738/)

[Sathasivam et al., Caspase-3: Cell death and disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12421763/)

[Zhang et al., Caspase-3 in neurodegenerative diseases (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/17656456/)

[Ferrer et al., Caspase signals in Alzheimer's disease (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12869855/)

[O'Reilly et al., Caspase-3 and ALS (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19368847/)

[Graham et al., Caspase-3 in Huntington's disease (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21693745/)

[Wang et al., Caspase-3 inhibition in stroke (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/29467890/)

[Yuan et al., Caspase-3 activation in Parkinson's disease models (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20855450/)

[Das et al., Caspase-3 and cognitive decline (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26189365/)

[Hyman et al., Caspase activation in AD (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24791720/)

[D'Amelio et al., Caspase-3 in synaptic plasticity (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22687853/)

[Friedlander et al., Caspase inhibition in neurodegeneration (2003) (2003)](https://pubmed.ncbi.nlm.nih.gov/12869684/)

[Onyango et al., Mitochondrial apoptosis in PD (2005) (2005)](https://pubmed.ncbi.nlm.nih.gov/15963386/)

[Unknown, Mattson, Apoptosis in neurodegenerative disorders (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10766168/)

[Wolfe et al., Caspase-3 substrates in neurodegeneration (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24142165/)

[Henderson et al., Caspase activation and tau pathology (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27523482/)

[Unknown, Bredesen, Caspase inhibition in AD therapy (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27054861/)

📖 View canonical wiki page →

Related Entities

CASPASE3PROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-caspase-3-protein
kg_node_id	CASPASE3PROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a614110f4742
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-caspase-3-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

65%

Debates

0

Incoming

13

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Caspase-3 Protein

Caspase-3 Protein

Overview

Pathway Diagram

Caspase-3 Protein

Overview

Pathway Diagram

Molecular Function and Biochemistry

Enzyme Classification and Structure

Domain Architecture

Substrate Specificity and Recognition

Activation Mechanism

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Stroke and Ischemic Injury

Therapeutic Targeting

Pharmacological Inhibitors

Challenges in Drug Development

Alternative Strategies

Biomarker Potential

Cerebrospinal Fluid (CSF) Biomarkers

Blood-Based Biomarkers

Imaging Biomarkers

Research Directions and Gaps

Recent Advances (2020-2024)

Critical Knowledge Gaps

Future Research Priorities

Interactions and Signaling Networks

Protein-Protein Interactions

Signaling Pathway Integration

Conclusion

See Also

External Links

Biochemical Kinetics and Catalytic Mechanism

Catalytic Mechanism

Kinetic Parameters

pH and Temperature Dependencies

Regulation of Caspase-3 Activity

Transcriptional Regulation

Post-Translational Modifications

Cellular Localization

Neuronal Specificity

Why Neurons Are Particularly Vulnerable

Neuronal Apop

Animal Models

Knock

Species Differences

Clinical Implications

Diagnostic Applications

Therapeutic Implications

Comparative An### Common

Future Directions

Emerging Therapeutic Approaches

Summary

References

💬 Discussion